Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics. / Masri, Bernard; Salahpour, Ali; Didriksen, Michael; Ghisi, Valentina; Beaulieu, Jean Martin; Gainetdinov, Raul R.; Caron, Marc G.
в: Proceedings of the National Academy of Sciences of the United States of America, Том 105, № 36, 09.09.2008, стр. 13656-13661.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics
AU - Masri, Bernard
AU - Salahpour, Ali
AU - Didriksen, Michael
AU - Ghisi, Valentina
AU - Beaulieu, Jean Martin
AU - Gainetdinov, Raul R.
AU - Caron, Marc G.
PY - 2008/9/9
Y1 - 2008/9/9
N2 - Since the unexpected discovery of the antipsychotic activity of chlorpromazine, a variety of therapeutic agents have been developed for the treatment of schizophrenia. Despite differences in their activities at various neurotransmitter systems, all clinically effective antipsychotics share the ability to interact with D2 class dopamine receptors (D2R). D2R mediate their physiological effects via both G protein-dependent and independent (β-arrestin 2-dependent) signaling, but the role of these D2R-mediated signaling events in the actions of antipsychotics remains unclear. We demonstrate here that while different classes of antipsychotics have complex pharmacological profiles at G protein-dependent D2R long isoform (D2 LR) signaling, they share the common property of antagonizing dopamine-mediated interaction of D2LR with β-arrestin 2. Using two cellular assays based on a bioluminescence resonance energy transfer (BRET) approach, we demonstrate that a series of antipsychotics including haloperidol, clozapine, aripiprazole, chlorpromazine, quetiapine, olanzapine, risperidone, and ziprasidone all potently antagonize the β-arrestin 2 recruitment to D2LR induced by quinpirole. However, these antipsychotics have various effects on D2LR mediated Gi/o protein activation ranging from inverse to partial agonists and antagonists with highly variable efficacies and potencies at quinpirole-induced cAMP inhibition. These results suggest that the different classes of clinically effective antipsychotics share a common molecular mechanism involving inhibition of D2LR/β- arrestin 2 mediated signaling. Thus, selective targeting of D2 LR/β-arrestin 2 interaction and related signaling pathways may provide new opportunities for antipsychotic development.
AB - Since the unexpected discovery of the antipsychotic activity of chlorpromazine, a variety of therapeutic agents have been developed for the treatment of schizophrenia. Despite differences in their activities at various neurotransmitter systems, all clinically effective antipsychotics share the ability to interact with D2 class dopamine receptors (D2R). D2R mediate their physiological effects via both G protein-dependent and independent (β-arrestin 2-dependent) signaling, but the role of these D2R-mediated signaling events in the actions of antipsychotics remains unclear. We demonstrate here that while different classes of antipsychotics have complex pharmacological profiles at G protein-dependent D2R long isoform (D2 LR) signaling, they share the common property of antagonizing dopamine-mediated interaction of D2LR with β-arrestin 2. Using two cellular assays based on a bioluminescence resonance energy transfer (BRET) approach, we demonstrate that a series of antipsychotics including haloperidol, clozapine, aripiprazole, chlorpromazine, quetiapine, olanzapine, risperidone, and ziprasidone all potently antagonize the β-arrestin 2 recruitment to D2LR induced by quinpirole. However, these antipsychotics have various effects on D2LR mediated Gi/o protein activation ranging from inverse to partial agonists and antagonists with highly variable efficacies and potencies at quinpirole-induced cAMP inhibition. These results suggest that the different classes of clinically effective antipsychotics share a common molecular mechanism involving inhibition of D2LR/β- arrestin 2 mediated signaling. Thus, selective targeting of D2 LR/β-arrestin 2 interaction and related signaling pathways may provide new opportunities for antipsychotic development.
KW - BRET
KW - Functional selectivity
KW - Schizophrenia
KW - Signaling
UR - http://www.scopus.com/inward/record.url?scp=51649084026&partnerID=8YFLogxK
U2 - 10.1073/pnas.0803522105
DO - 10.1073/pnas.0803522105
M3 - Article
C2 - 18768802
AN - SCOPUS:51649084026
VL - 105
SP - 13656
EP - 13661
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
SN - 0027-8424
IS - 36
ER -
ID: 36306992